Profile
International Journal of Gastroenterology Disorders & Therapy Volume 1 (2014), Article ID 1:IJGDT-108, 8 pages
http://dx.doi.org/10.15344/2393-8498/2014/108
Review Article
5-HT4 Receptor Agonists in the Treatment of Gastrointestinal Motility Disorders: Current Status and Perspective

Min Jung Lee 1,2*, Sunghak Choi1 and Weonbin Im1

1Dong-A ST Research Institute, 21 Geumhwa-ro, 105beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-905, Korea
2Department of Anatomy and Cell Biology, School of Medicine, Sungkyunkwan University, Suwon-si, Gyeonggi-do, 440-746, Korea
Min Jung Lee, Dong-A ST Research Institute, 21 Geumhwa-ro, 105beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-905, Korea, Tel: +82-31-280-1361; Fax: +82-31-282-8564; E-mail: liferadar@gmail.com
21 August 2014; 23 October 2014; 25 October 2014
Lee MJ, Choi S, Im W (2014) 5-HT4 Receptor Agonists in the Treatment of Gastrointestinal Motility Disorders: Current Status and Perspective. Int J Gastroenterol Disord Ther 1: 108. doi: http://dx.doi.org/10.15344/2393-8498/2014/108
This study was supported in part by a grant of the Health & Medical Technology R&D program, Ministry of Health, Welfare and Family Affairs, Republic of Korea (Grant: A100022).

Abstract

Background: 5-HT4 receptor plays important roles regulating gastrointestinal motility, enteric neuronal signaling and visceral pain in the gastrointestinal tract. Over the past decade, the 5-HT4 receptor has been highlighted as an attractive drug target for the treatment of gastrointestinal motility disorders such as irritable bowel syndrome, chronic constipation, functional dyspepsia, gastroparesis and so on. Objectives: This article aims to provide an overview of serotonin receptors related to the gastrointestinal motility disorders, and to address the characteristics of past, current and future 5-HT4 receptor agonists for treatment of functional gastrointestinal disorders, focusing on the pharmacology, efficacy and safety profile.

Methods: A literature search was performed using databases including MEDLINE (1974-July 2014), SCOPUS, Google Scholar, abstracts presented at the gastroenterology meetings and unpublished data from pharmaceutical companies. Specific search terms used were “5-HT4 receptor agonist”, “gastrointestinal motility disorder”, “irritable bowel syndrome” and “chronic constipation”.

Conclusion: In contrast to nonselective 5-HT4 receptor agonists such as tegaserod and cisapride, which were withdrawn due to cardiovascular adverse effects, several potent and selective 5-HT4 receptor agonists have been found to display the improved safety profile and the therapeutic potential in clinical trials and preclinical studies. These include agents such as prucalopride, velusetrag, naronapride, YKP10811 and DA-6886. These compounds differ in chemistry, efficacy, adverse effects and pharmacokinetics. The various properties of 5-HT4 receptor agonists will help us not only to enable adequate treatment to be tailored to the needs of each patient but also to stimulate further efforts to develop promising innovative drugs for gastrointestinal motility disorders.